Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Nabhan

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
BMJ Open Sport & Exercise Medicine|September 20, 2021
Exercise load monitoring: integrated approaches to advance the individualisation of exercise oncologyStephen J Carter, Marissa N Baranauskas, Tarah J Ballinger, et al.
British Journal of Cancer|July 19, 2012
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancerC Nabhan, D Villines, T V Valdez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2020
Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma"A M Evens, K R Carson, J Kolesar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphomaA M Evens, K R Carson, J Kolesar, et al.
Journal of Chiropractic Medicine|January 19, 2016
The American Chiropractic Board of Sports Physicians Position Statement on Pre-Participation Examinations: An Expert ConsensusWilliam J Moreau, Dustin C Nabhan, Christopher Roecker, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational statusE B Faber, Y Baca, J Xiu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJ S Abramson, T Feldman, A R Kroll-Desrosiers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practicesA K Nooka, C Nabhan, X Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patientsA R Mato, B T Hill, N Lamanna, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
BMJ Open Sport & Exercise Medicine|September 20, 2021
Exercise load monitoring: integrated approaches to advance the individualisation of exercise oncologyStephen J Carter, Marissa N Baranauskas, Tarah J Ballinger, et al.
British Journal of Cancer|July 19, 2012
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancerC Nabhan, D Villines, T V Valdez, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 6, 2020
Corrections to "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma"A M Evens, K R Carson, J Kolesar, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2013
A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphomaA M Evens, K R Carson, J Kolesar, et al.
Journal of Chiropractic Medicine|January 19, 2016
The American Chiropractic Board of Sports Physicians Position Statement on Pre-Participation Examinations: An Expert ConsensusWilliam J Moreau, Dustin C Nabhan, Christopher Roecker, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Exploring the differences in the tumor microenvironment and immuno-oncologic targets in pancreatic ductal adenocarcinomas (PDAC) according to <i>KRAS</i> mutational statusE B Faber, Y Baca, J Xiu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 7, 2014
Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapyJ S Abramson, T Feldman, A R Kroll-Desrosiers, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Examination of the follicular lymphoma international prognostic index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practicesA K Nooka, C Nabhan, X Zhou, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 29, 2017
Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patientsA R Mato, B T Hill, N Lamanna, et al.
Pageof 3